Advicenne S.A. (EPA:ALDVI)
France · Delayed Price · Currency is EUR 1.796
-0.064 (-3.44%)
Jul 14, 2026, 11:02 AM CET
Advicenne Company Description
Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and safe treatments for rare renal diseases in France and internationally.
It offers Sibnayal for the treatment of metabolic disorders. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures.
Advicenne S.A. was incorporated in 2007 and is headquartered in Paris, France.
Advicenne S.A.
| Country | France |
| Founded | 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Didier Laurens |
Contact Details
Address: 262 Rue du Faubourg Saint-Honore Paris, 75008 France | |
| Phone | 33 1 85 73 36 20 |
| Website | advicenne.com |
Stock Details
| Ticker Symbol | ALDVI |
| Exchange | Euronext Paris |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | FR0013296746 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Laurent Cassedanne | Deputy Chief Executive Officer, Deputy GM and Head Pharmacist and Director |
| Didier Laurens | General Director and Chairman of the Board |
| Isabelle Kervella | Chief Financial Officer |
| Dr. André Ulmann M.D., Ph.D. | Chief Medical Officer, Non-Voting Director and Director |
| Hege Hellstrom | Chief Commercial Officer |
| Robbie McCarthy | General Manager of Advicenne Inc. |